title: Markers of endothelial activation in preeclampsia.
abstract: BACKGROUND
  The study aimed at finding a laboratory approach to detect endothelial damage in normal pregnancy as well as in pregnancy complicated by preeclampsia using selected markers of endothelial activation.
  
  
  METHODS
  A total of 403 healthy pregnant women without a history of deep vein thrombosis and/or hypertension were prospectively studied. From all women, venous blood was collected before the end of the 1st trimester, between weeks 24 and 28 of gestation, and in the 3rd trimester (weeks 34-36). Assays of tissue plasminogen activator, plasminogen activator inhibitor-1, von Willebrand factor activity and antigen, thrombomodulin, endothelial protein C receptor, and endothelial microparticles activated by TF were performed.
  
  
  RESULTS
  When comparing women who developed preeclampsia during pregnancy (the average levels were 23.41 μg/L, 34.33 μg/L, and 53.56 μg/L in the 1st, 2nd, and 3rd trimesters, respectively) with healthy pregnant women (the average levels were 19.05 μg/L, 28.47 μg/L, and 39.86 μg/L in the 1st, 2nd, and 3rd trimesters, respectively) significant differences in the levels of thrombomodulin were found in all three trimesters. By contrast, no statistically significant differences in the levels of vWF (both antigen and activity), t-PA, EPCR, EMPs, MMP-2, MMP-9, and TIMP-9 were found in any trimesters in the same group.
  
  
  CONCLUSIONS
  Pregnancy and preeclampsia strongly influence the levels of studied markers. The findings of this work confirm the possible predictive potential of thrombomodulin and PA-1.
authors: Martin
authors: M
authors: Prochazka
authors: Jana
authors: J
authors: Procházková
authors: Marek
authors: M
authors: Lubušký
authors: Radovan
authors: R
authors: Pilka
authors: Jana
authors: J
authors: Úlehlová
authors: Igor
authors: I
authors: Michalec
authors: Petr
authors: P
authors: Polák
authors: Marian
authors: M
authors: Kacerovský
authors: Luděk
authors: L
authors: Slavik
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000097:blood; D015415:Biomarkers / Q000097:blood*; D016022:Case-Control Studies; D000074283:Endothelial Protein C Receptor; D004730:Endothelium, Vascular / Q000503:physiopathology; D005260:Female; D006801:Humans; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D011225:Pre-Eclampsia / Q000097:blood* / Q000503:physiopathology; D011247:Pregnancy; D011261:Pregnancy Trimester, First / Q000097:blood*; D011446:Prospective Studies; D011956:Receptors, Cell Surface / Q000097:blood; D012016:Reference Values; D018180:Thrombomodulin / Q000097:blood; D010959:Tissue Plasminogen Activator / Q000097:blood; D055815:Young Adult; D014841:von Willebrand Factor / Q000378:metabolism
chemical_list: D015703:Antigens, CD; D015415:Biomarkers; D000074283:Endothelial Protein C Receptor; C478370:PROCR protein, human; D017395:Plasminogen Activator Inhibitor 1; D011956:Receptors, Cell Surface; D018180:Thrombomodulin; D014841:von Willebrand Factor; D010959:Tissue Plasminogen Activator